ESR1 and breast neoplasm: Of the 4 hormone-positive treatment-naïve primary breast tumors with ESR1 mutations identified in the MSKCC dataset, follow-up times were shorter than 7 months and there were no progressions, distant recurrences, or deaths, precluding meaningful interrogation of the prognostic impact of preexisting ESR1 mutations.